Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
Fresenius Medical Care investing additional $25M in Humacyte » 10:09
08/30/21
08/30
10:09
08/30/21
10:09
HUMA

Humacyte

$12.00 /

+0.06 (+0.50%)

, FMS

Fresenius Medical

$38.67 /

-0.37 (-0.95%)

, AHAC

Alpha Healthcare Acquisition

$10.96 /

+ (+0.00%)

Fresenius Medical Care…

Fresenius Medical Care announced it is investing an additional $25M in the U.S. medical company Humacyte (HUMA). In connection with the merger of Humacyte with a special purpose acquisition company, or SPAC, Alpha Healthcare Acquisition (AHAC), Fresenius Medical Care is increasing its position in the newly combined entity as the lead investor of a private investment in public equity, or PIPE. Fresenius Medical Care acquired a stake in Humacyte in 2018 for $150M and agreed then on a strategic partnership. The combined company, which will be called Humacyte, is listed and trades on the Nasdaq exchange under HUMA. Fresenius Medical Care's original stake in Humacyte will be exchanged for shares in the combined company.

ShowHide Related Items >><<
HUMA Humacyte
$12.00 /

+0.06 (+0.50%)

FMS Fresenius Medical
$38.67 /

-0.37 (-0.95%)

AHAC Alpha Healthcare Acquisition
$10.96 /

+ (+0.00%)

HUMA Humacyte
$12.00 /

+0.06 (+0.50%)

04/09/21 Lake Street
Lake Street starts Alpha Healthcare Acquisition at Buy ahead of Humacyte closing
FMS Fresenius Medical
$38.67 /

-0.37 (-0.95%)

08/11/21 JPMorgan
Fresenius Medical price target raised to EUR 61.30 from EUR 58.80 at JPMorgan
08/04/21 Societe Generale
Fresenius Medical price target raised to EUR 71 from EUR 64 at Societe Generale
07/21/21 Deutsche Bank
Fresenius Medical price target raised to EUR 67 from EUR 65 at Deutsche Bank
07/20/21 UBS
Fresenius Medical price target raised to EUR 77 from EUR 74 at UBS
AHAC Alpha Healthcare Acquisition
$10.96 /

+ (+0.00%)

07/20/21 Benchmark
Alpha Healthcare Acquisition initiated with a Buy at Benchmark
04/09/21 Lake Street
Alpha Healthcare Acquisition initiated with a Buy at Lake Street
AHAC Alpha Healthcare Acquisition
$10.96 /

+ (+0.00%)

HUMA Humacyte
$12.00 /

+0.06 (+0.50%)

AHAC Alpha Healthcare Acquisition
$10.96 /

+ (+0.00%)

Options
Six new option listings and seven option delistings on August 27th » 08:30
08/27/21
08/27
08:30
08/27/21
08:30
CZOO

Cazoo

$8.73 /

-0.07 (-0.80%)

, GGPI

Gores Guggenheim

$9.85 /

+0.06 (+0.61%)

, HUMA

Humacyte

/

+

, IRNT

IronNet

$12.85 /

+2.73 (+26.98%)

, PRVA

Privia Health

$32.64 /

+0.29 (+0.90%)

, VLTA

Volta

/

+

, AHAC

Alpha Healthcare Acquisition

$10.96 /

+0.8 (+7.87%)

, AJAX

Ajax I

/

+

, DFNS

LGL Systems Acquisition

/

+

, MXIM

Maxim Integrated

$103.04 /

+ (+0.00%)

, SNPR

Tortoise Acquisition Corp. II

/

+

, USCR

U.S. Concrete

$73.98 /

+ (+0.00%)

New option listings for…

New option listings for August 27th include Cazoo Group Ltd (Class A Stock) (CZOO), Gores Guggenheim Inc (Class A Stock) (GGPI), Humacyte Inc (HUMA), IronNet Inc (Class A Stock) (IRNT), Privia Health Group Inc (PRVA), and Volta Inc (Class A Stock) (VLTA). Option delistings effective August 27th include Alpha Healthcare Acquisition Corporation (Class A Stock) (AHAC), Capri Listco (Class A Stock) (AJAX), LGL Systems Acquisition Corp (Class A Stock) (DFNS), iShares International Preferred Stock ETF (IPFF), Maxim Integrated Products Inc (MXIM), Tortoise Acquisition Corp II (Class A Stock) (SNPR), and US Concrete Inc (USCR).

ShowHide Related Items >><<
VLTA Volta
/

+

USCR U.S. Concrete
$73.98 /

+ (+0.00%)

SNPR Tortoise Acquisition Corp. II
/

+

PRVA Privia Health
$32.64 /

+0.29 (+0.90%)

MXIM Maxim Integrated
$103.04 /

+ (+0.00%)

IRNT IronNet
$12.85 /

+2.73 (+26.98%)

HUMA Humacyte
/

+

GGPI Gores Guggenheim
$9.85 /

+0.06 (+0.61%)

DFNS LGL Systems Acquisition
/

+

AJAX Ajax I
/

+

AHAC Alpha Healthcare Acquisition
$10.96 /

+0.8 (+7.87%)

CZOO Cazoo
$8.73 /

-0.07 (-0.80%)

GGPI Gores Guggenheim
$9.85 /

+0.06 (+0.61%)

HUMA Humacyte
/

+

04/09/21 Lake Street
Lake Street starts Alpha Healthcare Acquisition at Buy ahead of Humacyte closing
IRNT IronNet
$12.85 /

+2.73 (+26.98%)

PRVA Privia Health
$32.64 /

+0.29 (+0.90%)

08/10/21 Credit Suisse
Oak Street-driven dip provides opportunity in Cano, Privia, says Credit Suisse
08/09/21 Piper Sandler
Piper says Privia pullback due to market 'misinterpreting' new product news
07/14/21 Piper Sandler
Privia Health price target raised to $48 from $40 at Piper Sandler
06/30/21 Credit Suisse
Privia Health price target raised to $57 from $44 at Credit Suisse
VLTA Volta
/

+

AHAC Alpha Healthcare Acquisition
$10.96 /

+0.8 (+7.87%)

07/20/21 Benchmark
Alpha Healthcare Acquisition initiated with a Buy at Benchmark
04/09/21 Lake Street
Alpha Healthcare Acquisition initiated with a Buy at Lake Street
AJAX Ajax I
/

+

DFNS LGL Systems Acquisition
/

+

MXIM Maxim Integrated
$103.04 /

+ (+0.00%)

08/19/21 Deutsche Bank
Maxim Integrated price target raised to $107 from $104 at Deutsche Bank
08/03/21 Barclays
Maxim Integrated price target raised to $100 from $95 at Barclays
05/20/21 Deutsche Bank
Maxim Integrated price target raised to $104 from $100 at Deutsche Bank
05/20/21 Deutsche Bank
Analog Devices price target raised to $165 from $160 at Deutsche Bank
SNPR Tortoise Acquisition Corp. II
/

+

USCR U.S. Concrete
$73.98 /

+ (+0.00%)

06/15/21 CJS Securities
U.S. Concrete downgraded to Market Perform from Outperform at CJS Securities
06/08/21 DA Davidson
U.S. Concrete price target raised to $74 from $55 at DA Davidson
04/14/21 Truist
U.S. Concrete price target raised to $65 from $35 at Truist
02/25/21 DA Davidson
U.S. Concrete price target raised to $50 from $30 at DA Davidson
USCR U.S. Concrete
$73.98 /

+ (+0.00%)

PRVA Privia Health
$32.64 /

+0.29 (+0.90%)

MXIM Maxim Integrated
$103.04 /

+ (+0.00%)

  • 29
    Apr
USCR U.S. Concrete
$73.98 /

+ (+0.00%)

SNPR Tortoise Acquisition Corp. II
/

+

MXIM Maxim Integrated
$103.04 /

+ (+0.00%)

GGPI Gores Guggenheim
$9.85 /

+0.06 (+0.61%)

USCR U.S. Concrete
$73.98 /

+ (+0.00%)

PRVA Privia Health
$32.64 /

+0.29 (+0.90%)

MXIM Maxim Integrated
$103.04 /

+ (+0.00%)

GGPI Gores Guggenheim
$9.85 /

+0.06 (+0.61%)

DFNS LGL Systems Acquisition
/

+

AHAC Alpha Healthcare Acquisition
$10.96 /

+0.8 (+7.87%)

MXIM Maxim Integrated
$103.04 /

+ (+0.00%)

DFNS LGL Systems Acquisition
/

+

AJAX Ajax I
/

+

AHAC Alpha Healthcare Acquisition
$10.96 /

+0.8 (+7.87%)

Hot Stocks
Alpha Healthcare reports investor approval of combination with Humacyte » 13:00
08/24/21
08/24
13:00
08/24/21
13:00
AHAC

Alpha Healthcare Acquisition

$10.03 /

-0.15 (-1.47%)

, HUMA

Humacyte

/

+

Alpha Healthcare…

Alpha Healthcare Acquisition Corp. announced that its stockholders voted to approve the previously announced business combination with Humacyte, Inc., a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial scale, and all other proposals presented at AHAC's special shareholder's meeting held on August 24, 2021. AHAC shareholders approved the business combination proposal with 99.5% votes in favor of the approximately 61.6% of AHAC votes cast at the meeting. Subject to the satisfaction or waiver of the other customary closing conditions, the business combination is expected to close on August 26, 2021. Following the closing, the combined company will operate as Humacyte, Inc. and on or about August 27, 2021, its shares of common stock are expected to begin trading on the Nasdaq Global Select Market under the new ticker symbols "HUMA."

ShowHide Related Items >><<
AHAC Alpha Healthcare Acquisition
$10.03 /

-0.15 (-1.47%)

AHAC Alpha Healthcare Acquisition
$10.03 /

-0.15 (-1.47%)

07/20/21 Benchmark
Alpha Healthcare Acquisition initiated with a Buy at Benchmark
04/09/21 Lake Street
Lake Street starts Alpha Healthcare Acquisition at Buy ahead of Humacyte closing
04/09/21 Lake Street
Alpha Healthcare Acquisition initiated with a Buy at Lake Street
HUMA Humacyte
/

+

AHAC Alpha Healthcare Acquisition
$10.03 /

-0.15 (-1.47%)

AHAC Alpha Healthcare Acquisition
$10.03 /

-0.15 (-1.47%)

Conference/Events
Alpha Healthcare Acquisition management to meet virtually with Benchmark » 04:55
08/19/21
08/19
04:55
08/19/21
04:55
AHAC

Alpha Healthcare Acquisition

$9.99 /

+0.01 (+0.10%)

Virtual Meetings to be…

Virtual Meetings to be held on August 18-19 hosted by Benchmark.

ShowHide Related Items >><<
AHAC Alpha Healthcare Acquisition
$9.99 /

+0.01 (+0.10%)

AHAC Alpha Healthcare Acquisition
$9.99 /

+0.01 (+0.10%)

07/20/21 Benchmark
Alpha Healthcare Acquisition initiated with a Buy at Benchmark
04/09/21 Lake Street
Lake Street starts Alpha Healthcare Acquisition at Buy ahead of Humacyte closing
04/09/21 Lake Street
Alpha Healthcare Acquisition initiated with a Buy at Lake Street
AHAC Alpha Healthcare Acquisition
$9.99 /

+0.01 (+0.10%)

AHAC Alpha Healthcare Acquisition
$9.99 /

+0.01 (+0.10%)

Over a month ago
Conference/Events
Alpha Healthcare Acquisition management to meet virtually with Benchmark » 04:55
08/18/21
08/18
04:55
08/18/21
04:55
AHAC

Alpha Healthcare Acquisition

$9.98 /

+ (+0.00%)

Virtual Meetings to be…

Virtual Meetings to be held on August 18-19 hosted by Benchmark.

ShowHide Related Items >><<
AHAC Alpha Healthcare Acquisition
$9.98 /

+ (+0.00%)

AHAC Alpha Healthcare Acquisition
$9.98 /

+ (+0.00%)

07/20/21 Benchmark
Alpha Healthcare Acquisition initiated with a Buy at Benchmark
04/09/21 Lake Street
Lake Street starts Alpha Healthcare Acquisition at Buy ahead of Humacyte closing
04/09/21 Lake Street
Alpha Healthcare Acquisition initiated with a Buy at Lake Street
AHAC Alpha Healthcare Acquisition
$9.98 /

+ (+0.00%)

AHAC Alpha Healthcare Acquisition
$9.98 /

+ (+0.00%)

Hot Stocks
Humacyte announce addition of CCO, integration of commercial-scale manufacturing » 07:41
08/17/21
08/17
07:41
08/17/21
07:41
AHAC

Alpha Healthcare Acquisition

$9.98 /

-0.105 (-1.04%)

Humacyte announced…

Humacyte announced advancements in its commercial operations with the appointment of B.J. Scheessele as Chief Commercial Officer. In addition, Human Acellular Vessels produced in the Durham, N.C. facility are being administered to subjects throughout the U.S., Europe and Israel as part of clinical trials that are being conducted under two investigational new drug applications. Humacyte expects to submit a biologics license application to FDA in 2022 seeking approval of the HAV for its initial indication in vascular trauma. Scheessele will provide leadership, direction and strategic vision to drive the commercial launch of the HAV in its initial vascular indications and follow-on market expansion. Prior to joining Humacyte, Scheessele served as Executive Vice President of Global Marketing for Quest Medical Imaging. Humacyte's large-scale, commercial manufacturing systems, known as "Luna200", are housed in its 83,000-square-foot bioprocessing facility in Durham, N.C. Each modular, automated Luna200 system, with enhanced process controls, can grow 200 HAVs at a time. Humacyte previously presented data from its Phase 2 comparability clinical trial evaluating HAVs manufactured in the Luna200 system at the International Conference on Tissue Engineering and Regenerative Medicine. Clinical results demonstrated comparable three-month safety and efficacy outcomes to the prior, pilot-scale systems previously used to manufacture the HAV. The Durham facility is fully operational and capable of supplying current clinical trial product needs in the U.S. The facility also achieved compliance with EU good manufacturing practices and Qualified Person Certification to allow product to be supplied to ongoing studies in Europe and Israel. On February 17, 2021, Alpha Healthcare Acquisition, a special purpose acquisition company, and Humacyte announced the execution of a definitive business combination agreement along with a fully committed $175 million PIPE financing agreement. On August 24, 2021, AHAC will hold a special shareholder's meeting to vote on the proposed business combination with Humacyte.

ShowHide Related Items >><<
AHAC Alpha Healthcare Acquisition
$9.98 /

-0.105 (-1.04%)

AHAC Alpha Healthcare Acquisition
$9.98 /

-0.105 (-1.04%)

07/20/21 Benchmark
Alpha Healthcare Acquisition initiated with a Buy at Benchmark
04/09/21 Lake Street
Lake Street starts Alpha Healthcare Acquisition at Buy ahead of Humacyte closing
04/09/21 Lake Street
Alpha Healthcare Acquisition initiated with a Buy at Lake Street
AHAC Alpha Healthcare Acquisition
$9.98 /

-0.105 (-1.04%)

AHAC Alpha Healthcare Acquisition
$9.98 /

-0.105 (-1.04%)

Conference/Events
Alpha Healthcare Acquisition management to meet virtually with Benchmark » 16:48
08/16/21
08/16
16:48
08/16/21
16:48
AHAC

Alpha Healthcare Acquisition

$9.98 /

-0.105 (-1.04%)

Virtual Meetings to be…

Virtual Meetings to be held on August 18-19 hosted by Benchmark.

ShowHide Related Items >><<
AHAC Alpha Healthcare Acquisition
$9.98 /

-0.105 (-1.04%)

AHAC Alpha Healthcare Acquisition
$9.98 /

-0.105 (-1.04%)

07/20/21 Benchmark
Alpha Healthcare Acquisition initiated with a Buy at Benchmark
04/09/21 Lake Street
Lake Street starts Alpha Healthcare Acquisition at Buy ahead of Humacyte closing
04/09/21 Lake Street
Alpha Healthcare Acquisition initiated with a Buy at Lake Street
AHAC Alpha Healthcare Acquisition
$9.98 /

-0.105 (-1.04%)

AHAC Alpha Healthcare Acquisition
$9.98 /

-0.105 (-1.04%)

Hot Stocks
Alpha Healthcare, Humacyte nominees for election to board of directors » 07:39
08/13/21
08/13
07:39
08/13/21
07:39
AHAC

Alpha Healthcare Acquisition

$9.98 /

-0.035 (-0.35%)

Alpha Healthcare…

Alpha Healthcare Acquisition announced the nominees who will stand for election/reelection to its board of directors during the August 24, 2021, AHAC special shareholder's meeting to vote on the proposed business combination with Humacyte. The post-combination Board will be comprised of 11 directors, including seven independent directors. Gordon Binder, former CEO of Amgen; Emery Brown, M.D., Ph.D.; Mike Constantino, Director, 9 Meters Biopharma; Todd Pope, CEO of WellAir; Rajiv Shukla, chairman and CEO of Alpha Healthcare Acquisition; Sue Windham-Bannister, Director, St. Jude Medical Center; Laura Niklason, M.D., Ph.D., founder and CEO of Humacyte; Kathleen Sebelius, former Secretary of the Department of Health and Human Services; Brady Dougan, CEO of Exos Financial; Max Wallace, JD, former CEO of Trimeris; Jeffrey Lawson, M.D., Ph.D., Chief Surgical Officer of Humacyte. Subject to approval by the AHAC stockholders, the changes to the Board of Directors will be effective at the closing of the business combination between Humacyte and AHAC, expected in the third quarter of 2021. On February 17, 2021, AHAC, a special purpose acquisition company, and Humacyte announced the execution of a definitive business combination agreement along with a fully committed $175M PIPE financing agreement.

ShowHide Related Items >><<
AHAC Alpha Healthcare Acquisition
$9.98 /

-0.035 (-0.35%)

AHAC Alpha Healthcare Acquisition
$9.98 /

-0.035 (-0.35%)

07/20/21 Benchmark
Alpha Healthcare Acquisition initiated with a Buy at Benchmark
04/09/21 Lake Street
Lake Street starts Alpha Healthcare Acquisition at Buy ahead of Humacyte closing
04/09/21 Lake Street
Alpha Healthcare Acquisition initiated with a Buy at Lake Street
AHAC Alpha Healthcare Acquisition
$9.98 /

-0.035 (-0.35%)

AHAC Alpha Healthcare Acquisition
$9.98 /

-0.035 (-0.35%)

Hot Stocks
Humacyte announces publication of in vivo data on BVP » 07:44
08/11/21
08/11
07:44
08/11/21
07:44
AHAC

Alpha Healthcare Acquisition

$10.01 /

+ (+0.00%)

Humacyte announced…

Humacyte announced laboratory and preclinical data demonstrating the potential to engineer a biovascular pancreas as a method to transplant pancreatic islet cells for the long-term treatment of type 1 diabetes have been published in the Journal of Tissue Engineering. The manuscript, entitled, "Development of a Bioartificial Vascular Pancreas," reports in vivo, in vitro and in silico data supporting the potential of the biovascular pancreas technology platform to overcome current limitations of islet cell transplantation and offer an effective way to transplant pancreatic islet cells. Humacyte is developing the biovascular pancreas, or BVP, leveraging its human acellular vessels as a vascular scaffold, to be implanted in an outpatient procedure. The published data expand upon findings presented in June 2021 at the American Transplant Congress 2021 Virtual Connect, which demonstrated that pancreatic islet cells embedded in the outer matrix of an acellular vessel can create a working BVP in preclinical models. On February 17, 2021, Alpha Healthcare Acquisition, a special purpose acquisition company, and Humacyte announced the execution of a definitive business combination agreement along with a fully committed $175M PIPE financing agreement.

ShowHide Related Items >><<
AHAC Alpha Healthcare Acquisition
$10.01 /

+ (+0.00%)

AHAC Alpha Healthcare Acquisition
$10.01 /

+ (+0.00%)

07/20/21 Benchmark
Alpha Healthcare Acquisition initiated with a Buy at Benchmark
04/09/21 Lake Street
Lake Street starts Alpha Healthcare Acquisition at Buy ahead of Humacyte closing
04/09/21 Lake Street
Alpha Healthcare Acquisition initiated with a Buy at Lake Street
AHAC Alpha Healthcare Acquisition
$10.01 /

+ (+0.00%)

AHAC Alpha Healthcare Acquisition
$10.01 /

+ (+0.00%)

Conference/Events
Alpha Healthcare Acquisition management to meet virtually with Benchmark » 04:55
08/11/21
08/11
04:55
08/11/21
04:55
AHAC

Alpha Healthcare Acquisition

$10.01 /

+ (+0.00%)

Virtual Meeting to be…

Virtual Meeting to be held on August 11 hosted by Benchmark.

ShowHide Related Items >><<
AHAC Alpha Healthcare Acquisition
$10.01 /

+ (+0.00%)

AHAC Alpha Healthcare Acquisition
$10.01 /

+ (+0.00%)

07/20/21 Benchmark
Alpha Healthcare Acquisition initiated with a Buy at Benchmark
04/09/21 Lake Street
Lake Street starts Alpha Healthcare Acquisition at Buy ahead of Humacyte closing
04/09/21 Lake Street
Alpha Healthcare Acquisition initiated with a Buy at Lake Street
AHAC Alpha Healthcare Acquisition
$10.01 /

+ (+0.00%)

AHAC Alpha Healthcare Acquisition
$10.01 /

+ (+0.00%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.